Shares of Amag Pharmaceuticals Inc. sank Thursday, a day after the anemia drug maker said it is no longer considering any M&A deal and has no plans of selling itself.
THE SPARK: Amag said it has decided to focus on improving sales of its drug Feraheme. The company said in November it had hired Jefferies & Co. to evaluate options for the company, including a possible M&A sale.
On Wednesday, Amag said it named William Heiden as its new president and CEO and would shift its “focus from an active sale process” to business development and he growth of Feraheme. The company said Frank Thomas, who became interim CEO in November after Brian Pereira resigned, will go back to being chief operating officer.
Read the full article at Bloomberg Businessweek
Read: more on dealtalk in pharma, biotech, life science partnering deal news, insights and glossary
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity